Earnings Report /

Beximco Pharmaceuticals: FY21 – Annual NPAT posted c46% yoy growth

  • EPS of the company stood at BDT 11.5 (NPAT BDT 5,126mn) in FY21, implying c46% growth

  • Q4 FY21 EPS stood at BDT 3.26 against BDT 1.99

  • BXPHAR declared BDT 3.5/share cash dividend

Tanay Kumar Roy
Tanay Kumar Roy

Research Analyst

Shopnil Paul
Shopnil Paul

Research Associate

IDLC Securities
25 October 2021
Published by